Connor, Clark & Lunn Investment Management (CC&L)’s Cymabay Therapeutics CBAY Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-104,271	Closed	-$1.14M	–	1597
2023 Q2	$1.14M	Sell	104,271 -236,367	-69%	-$2.2M	0.01%	755
2023 Q1	$2.97M	Buy	340,638 +50,464	+17%	+$404K	0.02%	470
2022 Q4	$1.82M	Buy	290,174 +25,112	+9%	+$95.4K	0.01%	561
2022 Q3	$928K	Buy	265,062 +119,149	+82%	+$428K	0.01%	678
2022 Q2	$430K	Buy	145,913 +78,692	+117%	+$188K	﹤0.01%	814
2022 Q1	$209K	Buy	+67,221	New	+$212K	﹤0.01%	937
2021 Q1	–	Sell	-88,837	Closed	-$510K	–	1121
2020 Q4	$510K	Sell	88,837 -95,557	-52%	-$723K	﹤0.01%	722
2020 Q3	$1.33M	Sell	184,394 -60,936	-25%	-$326K	0.01%	564
2020 Q2	$856K	Buy	245,330 +128,755	+110%	+$372K	0.01%	647
2020 Q1	$173K	Buy	116,575 +88,925	+322%	+$149K	﹤0.01%	883
2019 Q4	$54K	Buy	+27,650	New	+$104K	﹤0.01%	896